John Ashcroft
YOU?
Author Swipe
View article: Advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma: A British Society of Haematology and <scp>UK</scp> Myeloma Society Good Practice Paper
Advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma: A British Society of Haematology and <span>UK</span> Myeloma Society Good Practice Paper Open
Summary This Good Practice Paper provides recommendations for the use of advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma. It describes how advanced imaging contributes to optimal healthcare resource util…
View article: Pathways of patients with chronic haematological malignancies: a report from the UK’s population-based HMRN
Pathways of patients with chronic haematological malignancies: a report from the UK’s population-based HMRN Open
Background Arising in blood and lymph-forming tissues, haematological malignancies (leukaemias, lymphomas and myelomas) are the fifth most common group of cancers. Around 60% are currently incurable and follow a chronic, remitting–relapsin…
View article: Inflammatory profile of lower risk myelodysplastic syndromes
Inflammatory profile of lower risk myelodysplastic syndromes Open
Summary The precise link between inflammation and pathogenesis of myelodysplastic syndrome (MDS) is yet to be fully established. We developed a novel method to measure ASC/NLRP3 protein specks which are specific for the NLRP3 inflammasome …
View article: Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper
Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper Open
Multiple myeloma is a bone marrow-based plasma cell tumour that develops from asymptomatic pre-cursor conditions smouldering myeloma and monoclonal gammopathy of uncertain significance and all are characterised by the presence of a monoclo…
View article: Data from A Gene Expression–Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment
Data from A Gene Expression–Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment Open
Purpose: Myeloma bone disease impairs quality of life and is associated with impaired survival. Even with effective bisphosphonate treatment, a significant proportion of patients still develop skeletal-related events (SRE). Identifying suc…
View article: Supplementary Tables 1-4 from A Gene Expression–Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment
Supplementary Tables 1-4 from A Gene Expression–Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment Open
PDF file - 186KB
View article: Supplementary Figure 1 from A Gene Expression–Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment
Supplementary Figure 1 from A Gene Expression–Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment Open
PDF file - 28KB
View article: Supplementary Tables 1-4 from A Gene Expression–Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment
Supplementary Tables 1-4 from A Gene Expression–Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment Open
PDF file - 186KB
View article: Supplementary Figure 1 from A Gene Expression–Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment
Supplementary Figure 1 from A Gene Expression–Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment Open
PDF file - 28KB
View article: Data from A Gene Expression–Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment
Data from A Gene Expression–Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment Open
Purpose: Myeloma bone disease impairs quality of life and is associated with impaired survival. Even with effective bisphosphonate treatment, a significant proportion of patients still develop skeletal-related events (SRE). Identifying suc…
View article: Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers
Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers Open
Daratumumab is a CD38-directed monoclonal antibody indicated to treat multiple myeloma (MM). Daratumumab was initially administered intravenously (IV), subsequently a subcutaneous (SC) formulation was developed to increase convenience of a…
View article: Diagnostic delay in multiple myeloma: the legacy of the COVID-19 pandemic.
Diagnostic delay in multiple myeloma: the legacy of the COVID-19 pandemic. Open
The COVID-19 pandemic has had global healthcare impacts, including high mortality from SARS-CoV-2 infection in cancer patients; individuals with multiple myeloma (MM) are es-pecially susceptible to poor outcomes. However, even for MM patie…
View article: Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs
Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs Open
MM is associated with a significant number of hospital admissions and NHS costs. The majority of the hospital admissions are elective, but the highest burden in terms of costs relates to unplanned admissions, with numbers increasing over t…
View article: PF605 SYSTEMATIC LITERATURE REVIEW AND NETWORK‐META ANALYSIS COMPARING INDUCTION TREATMENTS FOR NEWLY DIAGNOSED MULTIPLE MYELOMA IN THE TRANSPLANT ELIGIBLE SETTING
PF605 SYSTEMATIC LITERATURE REVIEW AND NETWORK‐META ANALYSIS COMPARING INDUCTION TREATMENTS FOR NEWLY DIAGNOSED MULTIPLE MYELOMA IN THE TRANSPLANT ELIGIBLE SETTING Open
Background: Use of induction regimens containing immunomodulatory drugs and proteasome inhibitors have improved overall response rates (ORRs) and overall survival (OS) in transplant‐eligible (TE) patients with newly diagnosed multiple myel…
View article: Chart Review Across EU5 in MM Post-ASCT Patients
Chart Review Across EU5 in MM Post-ASCT Patients Open
The study highlights the diversity in current treatment patterns post-ASCT. Results suggest patients who receive maintenance therapy have a prolonged remission period, and as a result their associated healthcare resource utilization is spr…
View article: Healthcare resource utilisation associated with skeletal‐related events in European patients with multiple myeloma: Results from a prospective, multinational, observational study
Healthcare resource utilisation associated with skeletal‐related events in European patients with multiple myeloma: Results from a prospective, multinational, observational study Open
Objectives Patients with multiple myeloma ( MM ) often experience debilitating skeletal‐related events ( SRE s: pathologic fracture, radiation to bone [ RB ], surgery to bone [ SB ] or spinal cord compression [ SCC ]). This is the first co…
View article: Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial Open
The phase III British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X trial (MMX) demonstrated prospectively, for the first time, superiority of salvage autologous stem cell transplantation over chemother…